Advertisement Daiichi Sankyo Venezuela set to market Ranbaxy products - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Daiichi Sankyo Venezuela set to market Ranbaxy products

Daiichi Sankyo Venezuela, a subsidiary of Daiichi Sankyo Company, will market products of Ranbaxy Laboratories in Venezuela under the hybrid business model.

Daiichi Sankyo Venezuela, which has already started the promotion, would begin marketing Ranbaxy products.

Ranbaxy has been marketing its drugs in Venezuela through a local distributor.

With the deal, Daiichi Sankyo is expected to focus on Ranbaxy’s portfolio of medicines to promote the Hybrid Business Model.

Under the hybrid business model, Ranbaxy primarily focuses on generic medicine research both for itself and its parent firm, while the new drug discovery program is undertaken taken up by Daiichi Sankyo.